Puma Biotechnology Inc. (NYSE:PBYI)‘s stock had its “buy” rating restated by Stifel Nicolaus in a note issued to investors on Thursday. They presently have a $88.00 price objective on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price indicates a potential upside of 74.60% from the company’s previous close.

PBYI has been the subject of several other research reports. Credit Suisse Group AG upped their price objective on shares of Puma Biotechnology from $54.00 to $111.00 and gave the company an “outperform” rating in a research note on Thursday, September 22nd. RBC Capital Markets restated a “sector perform” rating on shares of Puma Biotechnology in a research note on Thursday, September 22nd. Citigroup Inc. set a $88.00 price objective on shares of Puma Biotechnology and gave the company a “buy” rating in a research note on Tuesday, September 20th. Zacks Investment Research upgraded shares of Puma Biotechnology from a “hold” rating to a “buy” rating and set a $51.00 price objective for the company in a research note on Friday, August 12th. Finally, JPMorgan Chase & Co. set a $89.00 price objective on shares of Puma Biotechnology and gave the company a “buy” rating in a research note on Tuesday, September 20th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $68.56.

Analyst Recommendations for Puma Biotechnology (NYSE:PBYI)

Puma Biotechnology (NYSE:PBYI) opened at 50.40 on Thursday. The stock’s market cap is $1.64 billion. The company has a 50 day moving average price of $51.65 and a 200 day moving average price of $43.63. Puma Biotechnology has a 52 week low of $19.74 and a 52 week high of $82.81.

A number of large investors have recently made changes to their positions in the stock. KCG Holdings Inc. purchased a new stake in shares of Puma Biotechnology during the third quarter worth approximately $1,002,000. Laurion Capital Management LP purchased a new stake in shares of Puma Biotechnology during the third quarter worth approximately $208,000. Stephens Inc. AR purchased a new stake in shares of Puma Biotechnology during the third quarter worth approximately $302,000. Morgan Stanley increased its stake in shares of Puma Biotechnology by 790.3% in the third quarter. Morgan Stanley now owns 128,889 shares of the biopharmaceutical company’s stock worth $8,642,000 after buying an additional 114,412 shares during the last quarter. Finally, Principal Financial Group Inc. purchased a new stake in shares of Puma Biotechnology during the third quarter worth approximately $295,000. Hedge funds and other institutional investors own 97.60% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent.

5 Day Chart for NYSE:PBYI

Receive News & Stock Ratings for Puma Biotechnology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc. and related stocks with our FREE daily email newsletter.